# Eupraxia Pharmaceuticals Inc. (EPRX)

Source: https://www.quantisnow.com/company/EPRX
Generated: 2026-11-13T06:57:38.544Z

- Ticker: EPRX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Pharmaceuticals and Biotechnology
- SEC CIK: 0001581178

## Latest EPRX news and filings

- 2026-11-12 22:20 UTC [SEC Form S-8] [SEC Form S-8 filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-eupraxia-pharmaceuticals-inc-6788833)
- 2026-11-10 22:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6784744)
- 2026-11-10 22:22 UTC [SEC Form SUPPL filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-suppl-filed-by-eupraxia-pharmaceuticals-inc-6784732)
- 2026-11-10 21:16 UTC [Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program](https://www.quantisnow.com/insight/eupraxia-pharmaceuticals-establishes-at-the-market-offering-program-6784220)
- 2026-11-10 21:16 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6784137)
- 2026-11-10 21:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6783793)
- 2026-11-10 21:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6783750)
- 2026-11-10 21:01 UTC [Earnings] [Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/eupraxia-pharmaceuticals-reports-third-quarter-2026-financial-results-6783732)
- 2026-11-09 12:39 UTC [Analyst Coverage Initiated] [RBC Capital Mkts initiated coverage on Eupraxia Pharmaceuticals with a new price target](https://www.quantisnow.com/insight/rbc-capital-mkts-initiated-coverage-on-eupraxia-pharmaceuticals-with-a-6780255)
- 2026-10-22 12:50 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6754609)
- 2026-10-22 12:30 UTC [Conference Announcement] [Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day](https://www.quantisnow.com/insight/eupraxia-pharmaceuticals-to-participate-at-upcoming-conferences-and-host-a-6754554)
- 2026-10-15 14:13 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6747688)
- 2026-10-15 12:00 UTC [Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis](https://www.quantisnow.com/insight/eupraxia-pharmaceuticals-reaches-its-enrollment-target-for-the-resolve-trial-6747287)
- 2026-10-09 12:27 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6742448)
- 2026-10-09 12:00 UTC [Conference Announcement] [Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences](https://www.quantisnow.com/insight/eupraxia-pharmaceuticals-to-present-at-upcoming-american-college-of-gastroenterology-6742383)
- 2026-09-30 12:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6730017)
- 2026-09-30 12:00 UTC [Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis](https://www.quantisnow.com/insight/eupraxia-pharmaceuticals-reports-52-week-data-from-the-highest-dose-cohort-6729984)
- 2026-09-24 12:37 UTC [Analyst Coverage Initiated] [Wedbush initiated coverage on Eupraxia Pharmaceuticals with a new price target](https://www.quantisnow.com/insight/wedbush-initiated-coverage-on-eupraxia-pharmaceuticals-with-a-new-price-6724950)
- 2026-09-08 12:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6707606)
- 2026-09-08 12:00 UTC [Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences](https://www.quantisnow.com/insight/eupraxia-pharmaceuticals-completes-transfer-to-the-nasdaq-global-select-market-6707537)
- 2026-09-02 00:09 UTC [SEC Form SUPPL filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-suppl-filed-by-eupraxia-pharmaceuticals-inc-6702122)
- 2026-08-25 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-eupraxia-pharmaceuticals-inc-6693436)
- 2026-08-19 19:34 UTC [Amendment: SEC Form F-10/A filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-f-10a-filed-by-eupraxia-pharmaceuticals-inc-6688188)
- 2026-08-13 17:03 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-eupraxia-pharmaceuticals-inc-6679917)
- 2026-08-13 12:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6679463)
- 2026-08-13 12:00 UTC [Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients](https://www.quantisnow.com/insight/eupraxia-pharmaceuticals-reports-symptom-response-data-from-its-ongoing-phase-6679381)
- 2026-08-11 21:24 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6676492)
- 2026-08-11 21:21 UTC [Earnings] [Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/eupraxia-pharmaceuticals-reports-second-quarter-2026-financial-results-6676478)
- 2026-08-06 01:53 UTC [SEC Form F-X] [SEC Form F-X filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-f-x-filed-by-eupraxia-pharmaceuticals-inc-6666806)
- 2026-08-06 01:11 UTC [SEC Form F-10 filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-f-10-filed-by-eupraxia-pharmaceuticals-inc-6666788)
- 2026-07-15 17:26 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6638088)
- 2026-07-13 20:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6635430)
- 2026-07-13 20:05 UTC [Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth](https://www.quantisnow.com/insight/eupraxia-pharmaceuticals-strengthens-executive-leadership-team-to-support-next-phase-6635318)
- 2026-07-07 20:20 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6630157)
- 2026-07-07 12:00 UTC [Leadership Update] [Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization](https://www.quantisnow.com/insight/eupraxia-pharmaceuticals-strengthens-board-with-three-industry-leaders-in-drug-6629484)
- 2026-06-26 13:19 UTC [Analyst Coverage Initiated] [Oppenheimer initiated coverage on Eupraxia Pharmaceuticals with a new price target](https://www.quantisnow.com/insight/oppenheimer-initiated-coverage-on-eupraxia-pharmaceuticals-with-a-new-price-6616895)
- 2026-06-22 15:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6610410)
- 2026-06-19 20:02 UTC [Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders](https://www.quantisnow.com/insight/eupraxia-pharmaceuticals-announces-voting-results-from-annual-general-meeting-of-6609718)
- 2026-05-29 18:17 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6578815)
- 2026-05-29 18:09 UTC [SEC Form 6-K] [SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-eupraxia-pharmaceuticals-inc-6578806)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/EPRX
- Earnings history: https://www.quantisnow.com/earnings/EPRX
- Dividend history: https://www.quantisnow.com/dividends/EPRX
- Insider transactions: https://www.quantisnow.com/insiders/EPRX
- Options chain: https://www.quantisnow.com/options/EPRX
- SEC 8-K filings only: https://www.quantisnow.com/company/EPRX/8-k
- RSS and alerts for EPRX: https://www.quantisnow.com/docs/rss-feeds.md